The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $2,843,497 in first-year total cost, median $1,421,749.
Most frequent study sections
- Special Emphasis Panel[ZRG1 ETTN-C (10)]1
- Special Emphasis Panel[ZRG1 ETTN-M (11)]1
Most frequent institutions
- NEUROP, INC.1
- OPTIMA NEUROSCIENCE, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2017 | Phase 1 Clinical Evaluation of NP10679, a GluN2B Selective, Context-Dependent NMDA Receptor Inhibitor for Subarachnoid Hemorrhage2R44NS071657-05 | KOSZALKA, GEORGE WALTERZACZEK, ROBERT | NEUROP, INC., GA | $2,163,892 | ZRG1 |
| 2015 | High Performance Seizure Monitoring and Alert System2R44NS064647-05A1 | SHIAU, DENG-SHAN | OPTIMA NEUROSCIENCE, INC., FL | $679,605 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.